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The macrophage-inducible C-type lectin (mincle) is part of the innate immune system
and acts as a pattern recognition receptor for pathogen-associated molecular patterns
(PAMPS) and damage-associated molecular patterns (DAMPs). Ligand binding induces
mincle activation which consequently interacts with the signaling adapter Fc receptor,
SYK, and NF-kappa-B. There is also evidence that mincle expressed on macrophages
promotes intestinal barrier integrity. However, little is known about the role of mincle
in hepatic fibrosis, especially in more advanced disease stages. Mincle expression
was measured in human liver samples from cirrhotic patients and donors collected
at liver transplantation and in patients undergoing bariatric surgery. Human results
were confirmed in rodent models of cirrhosis and acute-on-chronic liver failure (ACLF).
In these models, the role of mincle was investigated in liver samples as well as in
peripheral blood monocytes (PBMC), tissues from the kidney, spleen, small intestine,
and heart. Additionally, mincle activation was stimulated in experimental non-alcoholic
steatohepatitis (NASH) by treatment with mincle agonist trehalose-6,6-dibehenate (TDB).
In human NASH, mincle is upregulated with increased collagen production. In ApoE
deficient mice fed high-fat western diet (NASH model), mincle activation significantly
increases hepatic collagen production. In human cirrhosis, mincle expression is also
significantly upregulated. Furthermore, mincle expression is associated with the stage of
chronic liver disease. This could be confirmed in rat models of cirrhosis and ACLF. ACLF
was induced by LPS injection in cirrhotic rats. While mincle expression and downstream
signaling via FC receptor gamma, SYK, and NF-kappa-B are upregulated in the liver, they
are downregulated in PBMCs of these rats. Although mincle expressed on macrophages
might be beneficial for intestinal barrier integrity, it seems to contribute to inflammation
and fibrosis once the intestinal barrier becomes leaky in advanced stages of chronic
liver disease.
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INTRODUCTION
The macrophage-inducible Ca2+-dependent lectin receptor
(mincle) is a primary component of the innate immune response
and acts as a sensor for pathogen-associated molecular patterns
(PAMPS) and damage-associated molecular patterns (DAMPS)
and is expressed mainly on cell types of the myeloid lineage
(e.g., macrophages) (1). Trehalose-6,6-dimycolate (TDM) stands
out among the PAMPS that interact with mincle (2). The
mycobacterial cell wall glycolipid has strong immunomodulatory
functions. Binding of the ligand to mincle leads to interaction
with the signaling adapter FC receptor gamma chain (FCER1G)
(3). The formed receptor complex enables intracellular signaling
molecules to dock on the immunoreceptor tyrosine-based
activation motif (ITAM) and thereby transduce signaling in
immune cells. The downstream signaling of the complex
proceeds inter alia via spleen associated tyrosine kinase (SYK)
and the nuclear factor kappa-light-chain-enhancer (NF-κB) to
induce the gene expression of pro-inflammatory cytokines,
chemokines, and enzymes (4, 5). On the cellular level, mincle
stimulation promotes the inflammatory phenotype of mainly M1
macrophages (6, 7).
Mincle is known for its pro-inflammatory properties,
especially in non-alcoholic (NASH) and alcoholic steatohepatitis
(ASH) (8, 9), and might be involved in the activation of
myofibroblasts (8). In NASH, mincle is predominantly reported
to be involved in the formation of crown-like structures. In
these structures, dying cells are surrounded by infiltrating
macrophages, which promote adipose tissue inflammation and
fibrosis (10, 11). Similar structures have been described in NASH
livers, but not in other etiologies of chronic liver disease (12).
To date, only one study has investigated the role of mincle in
ASH in a murine model with mild fibrosis. This study identified
Kupffer cells, the macrophages of the liver, as the main source
for mincle expression. The inhibition of downstream signaling
by SYK inhibitors led to decreased production of inflammatory
markers (9).
In more advanced stages of chronic liver disease, an impaired
intestinal barrier followed by bacterial translocation into the
blood circulation are important events in the development
from stable liver cirrhosis toward acute-on-chronic liver failure
(ACLF) (13). Infiltrating bacteria or bacterial products lead to
chronic systemic inflammation (14). Mincle possibly plays an
important role in this process in two respects, namely integrity
of the intestinal barrier and systemic inflammation. It recognizes
gut bacteria that penetrate the Peyer’s patches and induces the
activation of immune cells to reinforce the intestinal barrier
and thus prevents systemic inflammation. Furthermore, mincle
deficiency leads to increased bacterial translocation and hepatic
inflammation (15). Since ACLF is accompanied by a high short-
term mortality of 30% within 28 days (16), targeting mincle
in advanced chronic liver disease potentially restores intestinal
barrier integrity and reduces bacterial translocation, thereby
possibly preventing ACLF development.
Since to date, there are only a few reports published about
the role of mincle in fibrosis and none about its role in more
advanced stages of chronic liver injury, this study aims to assess
the role of mincle in cirrhosis and ACLF in the liver and in other
organs that are highly affected by systemic inflammation.
MATERIALS AND METHODS
Human Liver Samples
Liver samples from cirrhotic patients were taken during liver
transplantation at the University of Bonn between 1999 and 2005.
Liver samples of non-cirrhotic donors were used as controls.
This study was approved by the local ethics committee of the
University of Bonn (029/13).
Liver samples of NASH patients were taken during bariatric
surgery at the St. Franziskus-Hospital (Cologne, Germany)
between 2018 and 2019. NASH was diagnosed in liver biopsies
independently by two experienced pathologists using the non-
alcoholic fatty liver disease activity score after Kleiner (17). Non-
alcoholic fatty liver diseases were ruled out for control individuals
with<5% of parenchymal steatosis. NASH patients had a Kleiner
score of 6 or 7, with at least 33% of parenchymal steatosis,
hepatocyte ballooning, lobular inflammation, and grade 2 or 3
fibrosis. This study was approved by the ethics committees of the
North Rhine-Westphalian Chamber of Medicine (2017110) and
of the University of Bonn (194/17).
Liver samples were immediately stored at −80◦C and cut
on dry ice to avoid thawing. The studies were performed in
accordance with the declaration of Helsinki and patients gave
their written informed consent.
Animals
Twelve-week-old apolipoprotein E knockout mice (ApoE−/−,
C57BL/6J background; Charles River, Wilmington, USA) were
used for induction of experimental NASH.
For induction of chronic liver disease and ACLF, male wild
type Sprague Dawley rats with an initial body weight of 180–
200 g were used. Rats were fed standard rat chow (Ssniff,
Soest, Germany).
All animals received water and chow ad libitum. The
animals were kept in individually ventilated cages at 22◦C
with a 12 h day/night cycle. All experiments were performed
in accordance with the German Animal Protection Law and
the guidelines of the animal care unit at the University of
Bonn (Haus für experimentelle Therapie, Bonn, Germany) and
approved by the relevant North Rhine-Westphalian state agency
for Nature, Environment, and Consumer Protection (LANUV,
Germany) (LANUV84-02.04.2014.A137).
Induction of Experimental NASH and
Administration of Mincle Agonist TDB
Mice were fed a high-fat, cholesterol-rich diet (western diet; WD)
containing 21% fat (with coconut oil), 19.5% casein, and 1.25%
cholesterol (Ssniff, Soest, Germany) for seven weeks to induce
NASH as described previously (18–21).
Trehalose-6,6-dibehenate (TDB) is a synthetic analog of the
mycobacterial cell wall glycolipid of trehalose-6,6-dimycolate
(TDM). TDB (dose 50 µg, Invitrogen, Karlsbad, CA, USA) was
injected s.c. once per week for 7 weeks. Control mice received
solvent (sodium chloride).
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Induction of Experimental Cirrhosis and
Acute-on-Chronic Liver Failure
To induce cirrhosis, bile duct ligation (BDL) was performed
as a model for cholestatic liver disease as described previously
(22, 23). To induce ACLF, rats received a single intraperitoneal
dose of lipopolysaccharide (LPS from E. coli O111:B4, Sigma–
Aldrich, St. Louis, USA, 6.25 mg/kg body weight) 25 days after
BDL and were sacrificed 72 h after injection. BDL and sham-
operated rats without LPS injection served as controls. Sodium
chloride was used as solvent.
Tissue and Blood Collection
At the end of the experiment, animals were anesthetized and
laparotomy was performed for tissue collection. Liver, kidney,
spleen, small intestine, and heart were stored at −80◦C until
further use as described previously (18, 24). Blood samples were
collected in EDTA tubes (Sarstedt, Nümbrecht, Germany) for
isolation of peripheral blood mononuclear cells (PBMC). PBMCs
were isolated by density gradient centrifugation using Pancoll
(PAN-Biotec, Aidenbach, Germany) as described previously (25).
Cells were suspended in RPMI 1640 media with 10% fetal calf
serum and 10% dimethyl sulfoxide (Gibco, Carlsbad, USA) and
stored at−80◦C until further use.
Human liver samples were snap-frozen and stored at −80◦C
following excision as described previously (26).
Hepatic Hydroxyproline Content
Hydroxyproline content measurement was performed as
described previously (24, 26). Briefly, analog segments of 200mg
snap-frozen liver samples were dissolved and homogenized in
12N hydrochloric acid at 110◦C. Homogenized samples were
later dissolved in methanol, oxidized with chloramine T, and
finally reacted with Ehrlich’s reagent. Samples were measured
photometrically at 558 nm.
Quantitative Polymerase Chain Reaction
RNA isolation and quantitative polymerase chain reaction
(qPCR) were performed as described previously (24). Briefly,
total RNA was isolated with ReliaPrep RNA Miniprep Systems
and cDNA synthesis was performed by the ImProm-II Reverse
Transcription System (both Promega, Madison, WI, USA).
DNase digestion was performed to dispose of genomic DNA.
TaqMan gene expression assays (Thermo Fisher Scientific,
Waltham, MA, USA) were used (Supplemental Table 1) for
qPCR according to the manufacturer’s protocol on a 7300 Real-
Time PCR System (Applied Biosystems, Foster City, CA, USA).
Experiments were carried out in duplicates. Gene expression was
calculated by the 2−11Ct method and results were standardized
against 18S rRNA expression. Gene expression levels were shown
as x-fold expression compared with the respective control group.
Transcriptome Analysis
Transcriptome analysis was performed by OakLabs
(Hennigsdorf, Germany) using the Agilent Microarray XS
(Agilent Technologies, Santa Clara, USA). Briefly, Low Input
QuickAmp Labeling Kit (Agilent Technologies, Santa Clara,
USA) was used to create fluorescent complementary RNA
(cRNA) followed by hybridization to microarrays using the
Gene Expression Hybridization Kit (Agilent Technologies, Santa
Clara, USA). Fluorescence signals were detected using SureScan
Microarray Scanner (Agilent Technologies, Santa Clara, USA).
Western Blotting
Protein levels were analyzed by Western blot as described
previously (24, 26). Briefly, snap-frozen livers were homogenized
and diluted. The protein content of homogenates was determined
with the DC assay kit (Bio-Rad, Munich, Germany). Forty
micrograms of protein samples was subjected to SDS-PAGE
under reducing conditions (10% gels), and proteins were blotted
on nitrocellulose membranes. The membranes were blocked and
incubated with primary antibody against mincle (NBP1-49311,
Novus Biologicals, Littleton, USA). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) served as an endogenous control (sc-
166545 for human samples and sc-47724 for rodent samples;
both Santa Cruz Biotechnology, Santa Cruz, CA). Membranes
were incubated with the corresponding secondary antibody,
and blots were developed using enhanced chemiluminescence.
Protein quantification was performed by ImageJ (version 1.51q,
NIH, USA) and results were corrected for GAPDH levels.
Statistics
Statistical analyses were performed using PrismV.5.0 (GraphPad,
San Diego, CA). Data were expressed as mean ± standard error
of the mean (SEM). Groups were tested by Shapiro–Wilk-test
for normal distribution. Comparisons between two groups were
done by unpaired t-test or by non-parametric Mann–Whitney
U t-tests. Correlations were performed using SPSS V25 (IBM
SPSS Statistics for Windows, Version 25.0, Armonk, NY, USA).
Statistical analysis of patient characteristics and gene expressions
were done by calculation of Spearman’s correlation coefficient
with p-value. P < 0.05 were considered statistically significant.
For transcriptome analysis, statistical parameters were
computed between groups, and results are shown as log2-fold
change and visualized by heatmaps. P-values were calculated
using paired t-test and corrected according to the adaptive
Benjamini–Hochberg procedure. A FDR-adjusted p-value below
0.05 was considered statistically significant.
RESULTS
Mincle in NASH
The expression of mincle (gene CLEC4E) was assessed in
human liver samples from patients with NASH who underwent
bariatric surgery and in liver samples from donors for liver
transplantation. Mincle shows a tendency toward upregulation
in patients with NASH without reaching statistical significance
(Figure 1A). NASH patients show significantly higher
fibrogenesis (Figure 1B), as demonstrated by collagen 1 (gene
COL1A1), and inflammation (Figure 1C) than control patients,
as demonstrated by macrophage and Kupffer cell marker
EMR1 (gene ADGRE1). Furthermore, there is a trend toward
upregulation of αSMA (gene ACTA2), a surrogate marker of
hepatic stellate cell activation (Figure 1D). Interestingly, mincle
expression is upregulated with increased collagen 1 expression
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FIGURE 1 | Mincle in NASH. (A–D) Gene expression of mincle [gene CLEC4E; (A)], collagen [gene COL1A1; (B)], EMR1 [gene ADGRE1; (C)], and αSMA [gene
ACTA2; (D)] in liver samples of non-alcoholic steatohepatitis (NASH) patients and non-NASH controls (control). (E) Representative western blot showing protein levels
of mincle in NASH patients and non-NASH controls and quantification of the Western blots. (F) Hepatic collagen production, shown by measurement of hepatic
hydroxyproline content, in ApoE−/− fed WD with or without TDB treatment. *p < 0.05; **p < 0.01; #p < 0.1 using unpaired t-test (A,D) or non-parametric
Mann–Whitney U t-test (B,C,E,F) after testing for normal distribution.
(r = 0.550, p≤ 0.001, Supplemental Figure 1A) and with EMR1
expression (r = 0.398, p= 0.082, Supplemental Figure 1B).
In line with gene expression results, mincle protein was
significantly upregulated in liver samples of NASH patients in
comparison to liver samples of control patients (Figure 1E).
To further substantiate a close interaction of mincle and
fibrosis in NASH, we injected the mincle ligand Trehalose-
6,6-dibehenate (TDB) in a murine model of NASH that was
established in our lab (18) to stimulate mincle signaling. TDB
is a synthetic analog of the mycobacterial cell wall glycolipid
TDM. TDB significantly increases hepatic collagen accumulation
in comparison to untreated littermates as shown bymeasurement
of the hepatic hydroxyproline, a major component of collagen
(Figure 1F).
Hepatic Mincle in Cirrhosis and ACLF
Since the upregulation of mincle and its activity enhances
hepatic fibrogenesis in NASH, the more severe stages of
chronic liver disease were investigated. Mincle expression was
highly upregulated in human liver samples of cirrhotic patients
compared to donor livers and is associated with the severity of
chronic liver disease assessed by Child–Pugh score, reflecting
the prognosis of cirrhosis (Figure 2A). Furthermore, hepatic
mincle expression in cirrhotic patients is inversely associated with
platelet count (r = −0.372, p = 0.023), as a surrogate for the
severity of portal hypertension.
ACLF develops from liver cirrhosis and is associated with
systemic inflammation, multi-organ failure, and high short-term
mortality. To assess hepatic levels of mincle in this condition,
ACLF was triggered by lipopolysaccharide (LPS) administration
in a well-established rat model of cholestatic cirrhosis. Protein
levels of mincle were increased in liver samples of cirrhotic
and ACLF rats in comparison to sham-operated control animals
(Figure 2B).
The rodent models of cirrhosis and ACLF were also used
to examine downstream signaling of mincle via FC receptor
gamma chain (gene Fcer1g), spleen associated tyrosine kinase
(gene Syk), caspase recruitment domain family member 9 (gene
Card9) and nuclear factor kappa B (genes Nfkb1 and NFkb2)
in liver and in circulating immune cells via transcriptome
analysis (Figure 2C). In liver samples, the components of the
mincle downstream signaling were significantly upregulated in
both cirrhosis and ACLF compared to sham-operated control
animals (Figure 2D). Upregulation of the downstream signaling
in experimental cirrhosis and ACLF were confirmed by qPCR
for Fcer1g and Nfkb1 (Figure 2E). In PBMC, the expression
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FIGURE 2 | Hepatic mincle in cirrhosis and ACLF. (A) Gene expression of mincle (gene CLEC4E) in cirrhotic patients stratified by severity of chronic liver disease
compared to non-cirrhotic controls (NCC). (B) Representative Western blot showing protein levels of mincle in control, cirrhotic induced by bile-duct ligation (BDL),
and rats with acute-on-chronic liver failure (ACLF) induced by lipopolysaccharide (LPS) within cirrhosis and quantification of the Western blots. (C) Diagram of mincle
downstream signaling via FC receptor gamma chain (FCER1G), spleen associated tyrosine kinase (SYK), caspase recruitment domain family member 9 (CARD9) and
nuclear factor kappa B (NFκB) leading to expression of pro-inflammatory genes. (D) Heatmap of mincle and downstream signaling maker expression in cirrhotic and
ACLF livers. (E) Gene expression analysis of Clec4e, Fcer1g, and Nfkb1 by qPCR in cirrhotic and ACLF liver compared to sham-operated control. (F) Heatmap of
mincle and downstream signaling maker expression in cirrhotic and ACLF peripheral blood mononuclear cells (PBMC). Arrows indicate the respective band used for
quantification in cases when more than one band is shown in the representative Western blots. In heatmaps, statistical comparison was performed between cirrhosis
or ACLF and sham-operated control rats. Upregulation is marked by red colors and downregulation by blue colors. *p < 0.05; **p < 0.01; ***p < 0.001; #p < 0.1
using non-parametric Mann–Whitney U t-test or FDR-adjusted paired t-test for data from microarray assay.
profile of mincle signaling was almost unchanged in cirrhosis.
By contrast, a clear downregulation of the gene was observed in
ACLF (Figure 2F).
There is a clear dysregulation of mincle between liver and
PBMCs in cirrhosis and ACLF. Since cirrhosis and ACLF are
systemic diseases we also investigated mincle and its downstream
signaling in extrahepatic tissues.
Mincle in Extrahepatic Tissues in Cirrhosis
and ACLF
Inflammation in cirrhosis and, especially, in ACLF affects
extrahepatic organs (kidney, spleen) but is also maintained
and triggered by them (e.g., bacterial translocation from the
intestine). Therefore, mincle expression and signaling profile
were investigated in extrahepatic tissues. In spleen, protein levels
of mincle significantly increased in cirrhosis and showed a
stronger enhancement in ACLF (Figure 3A). The downstream
signaling profile was similar to the one observed in PBMC,
with minor changes of gene expression in cirrhosis but a
significant downregulation of the signaling components in
ACLF (Figure 3B). This could be mainly confirmed in qPCR
experiments. However, it seems that there was also a mincle-
independent splenic upregulation of Nfkb1 in ACLF (Figure 3C).
In kidney, protein levels of mincle increased in cirrhosis and in
ACLF (Figure 3D). As with higher renal mincle levels in cirrhosis
and ACLF, downstream signaling profile showed an upregulation
of the components in cirrhosis and in ACLF (Figure 3E) and was
confirmed by pPCR (Figure 3F). In tissue samples of the small
intestine, protein levels of mincle seemed to bring about a relative
increase comparable to the one observed in spleen and kidney
tissue samples (Figure 3G). However, in transcriptome analysis
of the small intestine, the mincle upregulation failed to translate
into an upregulation of the downstream signaling (Figure 3H).
Results from qPCR confirmed the transcriptome analysis, except
for a mincle-independent upregulation of Nfkb1 (Figure 3I). In
heart tissue, protein levels of mincle showed a similar increase
in the disease stages from healthy control via cirrhosis to ACLF
(Figure 3J). The downstream signaling profile showed a mild
increase, at least in some of the components in cirrhosis, but a
marked significant increase in ACLF (Figure 3K). These results
could be confirmed by qPCR experiments (Figure 3L).
Taken together, protein levels of mincle are increased in
cirrhosis and ACLF in all observed organs, with the highest
expression in ACLF. However, this upregulation does not lead
to enhanced downstream signaling in all organs. It rather
seems that there are two different expression profiles, one
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FIGURE 3 | Extrahepatic mincle in cirrhosis and ACLF. (A–C) Mincle in the spleen. (A) Representative Western blot showing protein levels of mincle in control,
cirrhotic, and ACLF rats and quantification of the Western blots. (B) Heatmap of mincle and downstream signaling maker expression in cirrhosis and ACLF. (C) Gene
expression of Clec4e, Fcer1g and Nfkb1 in cirrhosis and ACLF. (D–F) Mincle in kidney. (D) Representative Western blot showing protein levels of mincle in control,
cirrhotic, and ACLF rats and quantification of the Western blots. (E) Heatmap of mincle and downstream signaling maker expression in cirrhotic and ACLF. (F) Gene
expression of Clec4e, Fcer1g, and Nfkb1 in cirrhosis and ACLF. (G–I) Mincle in small intestine. (G) Representative Western blot showing protein levels of mincle in
control, cirrhotic and ACLF rats and quantification of the Western blots. (H) Heatmap of mincle and downstream signaling maker expression in cirrhotic and ACLF.
(I) Gene expression of Clec4e, Fcer1g, and Nfkb1 in cirrhosis and ACLF. (J–L) Mincle in heart. (J) Representative Western blot showing protein levels of mincle in
control, cirrhotic, and ACLF rats and quantification of the Western blots. (K) Heatmap of mincle and downstream signaling maker expression in cirrhotic and ACLF.
(L) Gene expression of Clec4e, Fcer1g, and Nfkb1 in cirrhosis and ACLF. Arrows indicate the respective band used for quantification in cases when more than one
band is shown in the representative Western blots. In heatmaps, statistical comparison was performed between cirrhosis, respectively, ACLF and sham-operated
control rats. Upregulation is marked by red colors and downregulation by blue colors. *p < 0.05; **p < 0.01; ***p < 0.001; #p < 0.1 using using non-parametric
Mann–Whitney U t-test or FDR-adjusted paired t-test for data from microarray assay.
that shows a marked upregulation of the mincle downstream
signaling, as in liver, kidney, and heart, and one that shows
a dysregulation of the downstream signaling, as in PBMC,
spleen, and the small intestine. Gene expression experiments
revealed a mincle-independent increase of Nfkb1 in organs with
dysregulated downstream signaling, which, however, was not
as prominent as Nfkb1 upregulation in organs with mincle-
dependent upregulation of the downstream signaling, such as
liver, kidney, and heart.
DISCUSSION
This study describes for the first time the mincle expression
in different stages of chronic liver disease especially in more
advanced stages of chronic liver disease and ACLF. Interestingly,
the downstream signaling of mincle under these conditions
seems not systemic. While mincle signaling is downregulated in
compartments of the immune system and the intestinal barrier, it
is upregulated in the other observed tissues including the liver.
To date, very little is known about the role of mincle in
chronic liver disease, particularly its hepatic function. In NASH,
mincle is involved in the formation of crown-like structures, in
which infiltrating macrophages attracted from dying adipocytes
surround these cells and thereby promote adipose tissue
inflammation and fibrosis (10, 11). Similar structures have also
been identified in liver tissue in experimental and human NASH
when macrophages aggregate around hepatocytes that contain
large lipid droplets, which significantly correlated with fibrosis.
Of note, these structures were primarily described for NASH—
but rarely for viral hepatitis—as a general mechanism for chronic
liver diseases. However, the impact of mincle on the progression
of liver disease was not investigated (12). This study complements
previous findings by providing additional data, especially in
human samples and provides evidence that mincle is upregulated
in NASH and its pro-fibrotic properties.
Moreover, mincle seems to play a role in chronic liver
diseases in general. Our study confirms previous data from
the murine model (9) and demonstrates that mincle is also
upregulated in more advanced stages of human chronic liver
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disease and that it is associated with disease progression
regardless of etiology. The correlation of mincle expression
with Child-Pugh score and platelet count as readouts for portal
hypertension, suggest that mincle is associated with the major
complication in cirrhosis promoting the development of systemic
inflammation and ACLF. Thereby, the degree of activation of
systemic inflammation can be used as a predictor for disease
progression and mortality. While in decompensated cirrhosis,
a partial activation of systemic inflammation with low short-
term mortality can be observed, ACLF is characterized by
complete activation of systemic inflammation and high short-
term mortality (27–29). The upregulation of inflammatory
markers is mediated primarily by myeloid cells and is associated
with activation of the immune response due to bacterial
translocation (30–32). Therefore, the assessment of mincle in
ACLF was of special interest for this study, since systemic
inflammation concurs with local inflammation in the liver.
Interestingly, Martínez-López et al. (15) reported that mincle
deficient mice showed increased bacterial translocation into the
circulation and increased hepatic inflammation. In fact, the
current study demonstrates a dysregulated mincle downstream
signaling in compartments of the immune system and intestinal
barrier in ACLF, namely PBMC, spleen and the small intestine.
In previous studies, we could demonstrate a specific blood
microbiome in decompensated cirrhosis (31). Therefore, the
dysregulated mincle signaling might contribute to bacterial
translocation and the development toward ACLF. Thus, there
exists a clear relationship between portal hypertension and
development of ACLF mediated by systemic inflammation
(13, 33). This relationship is supported by the fact that
systemic inflammation can be reduced if the underlying portal
hypertension is ameliorated by insertion of a transjugular
intrahepatic portosystemic shunt (34–36).
Although advanced chronic liver disease features systemic
inflammation, “sepsis-like” immune paralysis develops in
more severe stages facilitating secondary infections and
organ failure (37, 38). Mincle possibly plays an important
role in these apparently opposing observations, since the
dysregulation of mincle signaling in spleen and PBMC, as
important compartments of the immune system, could be
responsible for the failure to clear invading gut bacteria and
consequent systemic inflammation. This might also contribute
to the compartmentalization of the immune response in
decompensated cirrhosis and ACLF (32). This study proves that
upregulation of mincle in ACLF is not restricted to the liver but
is also found in other important compartments. However, mincle
upregulation does not necessarily translate into an upregulation
of the downstream signaling via FCER1G/SYK/CARD9/NFκB.
Downstream signaling of mincle is differently regulated
dependent on the compartment of the immune system and the
intestinal barrier. This finding indicates that mincle possibly
plays an important role in immune paralysis observed in ACLF.
The role of mincle in spleen and small intestine upon progression
of chronic liver disease remains uncertain and requires further
clarification, since some of the data from the microarray could
not be confirmed by qPCR. However, we can not exclude that
these discrepancies in the results are due to the two different
used methods as lack of convertibility between results generated
by microarray or qPCR has been reported (39, 40).
The co-occurrence of complications of advanced chronic
liver disease and systemic inflammation leads to extrahepatic
organ dysfunction promoting the development of ACLF. Renal
dysfunction in cirrhosis leads to ascites formation and implicates
inflammation by bacterial infections promoting progression
toward ACLF (41). Moreover, kidney failure is the most
common additional organ failure in ACLF originating probably
from inflammation and systemic hemodynamic instability
(42). The combination of vasoconstrictor terlipressin and
albumin provides the best treatment, probably by combining
hemodynamic as well as immunomodulatory properties (43).
Interestingly, in subarachnoid hemorrhage, a subtype of stroke,
albumin treatment attenuated activation of the immune response
in parenchymal macrophages of the central nervous system (44).
Therefore, the interaction of albumin and mincle in tissue-
resident macrophages may also be one of the beneficial effects
of albumin treatment in patients with advanced chronic liver
disease (38).
In addition to renal dysfunction, circulatory dysfunction also
plays an important role in the development of ACLF. Reduced
heart rate variability is a common feature of cirrhosis due to
systemic inflammation. Heart rate variability is further reduced
in patients developing ACLF and can be used to predict disease
progression and short-term mortality (45). Interestingly, mincle
is also expressed in cardiac tissue (46). We also observed an
upregulation of mincle in cardiac tissue in the model of ACLF.
This may be explained by cell dysfunction, whereby mincle
induces necroptosis (46).
The major limitation of this study is that mincle expression
was only measured in whole organ lysates but not in the
respective resident macrophage populations of each organ.
Mincle could be another integral component in the cross-talk
between macrophages and hepatic stellate cells that translates
macrophage-induced fibrosis. This study opens avenues for
the investigation of the processes behind dysregulated mincle
signaling in different compartments of the immune system.
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